Stocks moved in a mixed session, with a wave of corporate headlines and strategic updates driving notable swings across sectors. Alnylam Pharmaceuticals rose about 4% after unveiling a strategic artificial intelligence collaboration with Inceptive Nucleics valued at up to $2 billion, a move designed to accelerate the discovery of RNA interference therapeutics. Blackstone jumped roughly 8% as investors appeared to overlook news that the firm is limiting withdrawals from the Blackstone Private Credit fund amid a surge in redemption requests. The gain helped lift peers Ares Management and KKR, which advanced about 6% in sympathy with the broad risk-on impulse in financials and alternatives names.
Within the health care and consumer spaces, Humana traded higher, gaining more than 6% after Morgan Stanley raised its price target on the insurer to $249 a share, while keeping an underweight rating. The note suggested the target implies about 24% downside from the prior close, contrasting with the roughly 34% decline implied by the earlier target of $217. The move illustrates an uneven stance among analysts, even as the stock benefited from broad sector rotation and a more constructive view on certain near-term dynamics.
In the technology and semiconductor space, Broadcom shares fell nearly 15% after reporting fiscal second-quarter revenue of $22.19 billion, short of the $22.27 billion consensus expected by analysts polled by LSEG. Chief Executive Hock Tan reaffirmed the company’s revenue target for AI chips in fiscal 2027, projecting it to be “in excess of $100 billion.” The result underscored ongoing concerns about near-term demand and the sensitivity of large cap chipmakers to quarterly prints. The softness at Broadcom weighed on the broader AI semis complex, with Micron Technology off about 7%, Intel down 2%, Advanced Micro Devices down 4%, and Arm Holdings down roughly 5% as the sector reeled from the quarterly miss and subsequent guidance read-through.
Five Below fell about 13% despite delivering an outlook that topped some expectations, underscoring a nuanced reaction to guidance that still left investors cautious about consumer spending trends. The company projected second-quarter revenue between $1.18 billion and $1.20 billion versus a StreetAccount consensus around $1.15 billion. Same-store sales were expected to rise 7% to 9%, above the roughly 4.4% consensus, yet the stock traded lower on the back of the conservative setup for the rest of the year. Petco’s shares slumped about 8% after the retailer forecast current-quarter results that came in below Wall Street expectations. Petco sees second-quarter adjusted EBITDA of $110 million to $112 million, versus StreetAccount consensus near $115 million.
In cybersecurity, CrowdStrike shares declined about 6% after a cautious second-quarter guidance frame. The company projected second-quarter revenue of around $1.44 billion, just above a StreetAccount estimate of $1.30 billion, and adjusted earnings of roughly $1.16 to $1.17 per share, versus expectations near $1.16. Palo Alto Networks likewise moved lower in sympathy, reflecting a broader pullback in high-growth security names after the results from CrowdStrike and a softening near-term outlook.
Traveling down the distribution chain of consumer and apparel names, PVH Corp, the parent of Tommy Hilfiger and Calvin Klein, dropped about 20% after reiterating its full-year earnings guidance. The company posted a first-quarter earnings beat, but revenue was roughly in line with expectations, and the forceful reassessment by investors pushed the stock lower amid questions about top-line momentum for the year ahead.
On the health-insurer front, UnitedHealth Group advanced about 5% after Bank of America upgraded the stock to Buy from Neutral. The firm cited improving medical cost trends and supportive near-term data points that could set up a favorable second-quarter print, suggesting room for earnings upside relative to peers in the period ahead. In medical technology, Medtronic rose roughly 4% following BTIG’s upgrade to Buy from Neutral, with the firm arguing the company has an attractive top-line setup and trades at a discount to its peers, potentially offering upside as the year unfolds.
The day’s broader mood, however, remained cautious as investors weighed a mix of earnings results and guidance signals across sectors. The moves reflect an atmosphere where AI-related opportunities and macro-driven sentiment continue to shape stock-price reactions, even as individual names report divergent results and outlooks.
Key takeaways
- Price move: Alnylam +4% on AI-collaboration news; Broadcom -nearly 15% on a revenue miss; PVH -20% on cautious guidance after beating on earnings.
- Catalyst: Strategic AI partnerships and earnings-driven revisions were the primary differentiators, with several names signaling either upside in cost or revenue trajectories or disappointment in near-term demand.
- Key implication: The session underscores a bifurcated market where AI-enabled growth names and asset managers react to strategic moves, while hardware-focused chipmakers face near-term revenue headwinds that weigh on sentiment.
What drove the move
Alnylam’s announcement of a strategic AI collaboration with Inceptive Nucleics, valued at up to $2 billion, is the standout driver among health and biotech stocks. The collaboration centers on leveraging generative AI models to accelerate discovery of RNA interference therapeutics, a development investors may view as a potential accelerant for pipeline advancement and time-to-market for new treatments. CNBC notes that the move could translate into accelerated research timelines and potential productivity gains for Alnylam’s research operations, though the immediate financial impact remains a longer-term dynamic.
In the asset-management cohort, Blackstone’s rally followed news that the firm is limiting withdrawals from its Private Credit fund, a move traders interpreted as a controlled response to heightened redemption requests rather than a signal of stressed liquidity. By contrast, Broadcom’s quarterly results underscored a tougher near-term environment for AI-centric hardware, with revenue missing consensus and the management reiterating a buoyant but long-horizon AI-chip opportunity, pegged at over $100 billion in AI-chip revenue for fiscal 2027. The commentary suggests the market is pricing in a difficult near term for hardware suppliers even as the AI narrative remains intact over the multi-year horizon.
Consumer discretionary and apparel names drew caution around forward-looking guidance. Five Below’s outlook beat expectations on revenue timing and store-level performance, yet the stock sold off as investors digested a higher bar for the second half of the year. Petco’s more conservative second-quarter view reflects ongoing consumer spending headwinds and margin dynamics in a sector where value-oriented retailers are navigating margin pressures and recovery in foot traffic.
Market reaction
The session painted a portrait of a market selectively reacting to earnings deltas and strategic moves. The strongest moves were concentrated among alternative managers and AI-focused growth plays, while traditional hardware names faced a sharper reassessment after misses and cautious outlooks. The breadth of moves underscores investors’ preference for items with visible, near-term catalysts, and some willingness to posture ahead of next-quarter results from other major constituents.
What analysts are saying
Analysts’ reactions were mixed, with some incrementally revising near-term outlooks and others maintaining cautious stance. In Humana’s case, Morgan Stanley’s upgraded price target to $249 signaled a potential longer-term upside, even as the rating remained underweight. The bank’s commentary highlighted the contrast between an improved cost trajectory and the stock’s relative risk in its current multiple. In the health-tech space, BTIG’s upgrade of Medtronic to Buy suggested an attractive setup relative to peers and a focus on top-line momentum. Bank of America’s upgrade of UnitedHealth to Buy added a fresh positive data point for the insurer, aligning with a narrative of stabilizing medical-cost trends and supportive near-term performance indicators.
CNBC’s coverage notes that the day’s trading activity included several notable moves tied to earnings guidance and strategic partnerships, with analysts weighing both the cyclical sensitivity in semiconductors and the longer-term demand drivers in AI computing. The reporting team identified investors parsing whether AI investments will translate into near-term revenue acceleration and profitability, and how guidance from large-cap players might influence broader sector sentiment.
According to CNBC, Darla Mercado, Fred Imbert and Lisa Han contributed reporting on this story.
Bigger picture
Taken together, the day’s moves reflect a market balancing AI-sector optimism with the realities of near-term earnings prints. The AI thesis remains a meaningful theme for the tech and semiconductor complex, but investors are pricing in variability across companies’ ability to convert long-horizon AI opportunities into material quarterly results. The performance of asset managers on withdrawal-limitation news suggests that liquidity considerations remain in focus for alternative investments, even as managers emphasize strategic positioning around risk-adjusted returns.
From a macro standpoint, the firmer tone around select equities—particularly health insurers and technology beneficiaries—signals that investors are differentiating among names with tangible near-term catalysts and those facing structural or cyclical headwinds. As the rate and inflation backdrop continues to evolve, market participants will be watching guidance revisions, capital allocation signals, and the durability of any AI-related revenue streams across the coming quarters.
What to watch next: forthcoming earnings from major players in AI, semis, and health care, as well as evolving commentary on AI investment returns and liquidity dynamics in asset management. Investors will also be focused on any updates to guidance, cost control measures, and capital allocation strategies that could influence near-term stock performance in these crowded spaces.
